• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Metagenomi Inc.

    5/10/24 6:40:45 PM ET
    $MGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGX alert in real time by email
    SC 13G 1 tm2414167d1_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Metagenomi, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    59102M104

    (CUSIP Number)

     

    February 9, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    ¨       Rule 13d-1(c)

     

    x      Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

     

    Page 1 of 16 Pages

    Exhibit Index Contained on Page 15

     

     

    CUSIP NO. 59102M104 13G Page 2 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sozo Ventures - TrueBridge Fund II, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    581,577 shares. (1)
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    581,577 shares. (1)
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    581,577 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.6% (2)
    12 TYPE OF REPORTING PERSON* PN

     

    (1)All such shares are held of record by Sozo Ventures - TrueBridge Fund II, L.P. (“Fund II”). Sozo Ventures GP II, L.P. (“DGP II”), the general partner of Fund II, and Sozo Ventures UGP II, Ltd. (“UGP II”), the general partner of DGP II, may be deemed to have sole voting and dispositive power with respect to these securities. Phillip Wickham (“Wickham”) and Koichiro Nakamura (“Nakamura”), the directors of UGP II, may be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of Metagenomi, Inc. (the “Issuer”) outstanding as of March 15, 2024, as set forth in the Issuer’s Form 10-K filed with the Securities and Exchange Commission on March 27, 2024 (the “Form 10-K”).

     

     

    CUSIP NO. 59102M104 13G Page 3 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sozo Ventures GP II, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    581,577 shares. (1)
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    581,577 shares. (1)
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    581,577 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.6% (2)
    12 TYPE OF REPORTING PERSON* PN

     

    (1)All such shares are held of record by Fund II. DGP II, the general partner of Fund II, and UGP II, the general partner of DGP II, may be deemed to have sole voting and dispositive power with respect to these securities. Wickham and Nakamura, the directors of UGP II, may be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 4 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sozo Ventures UGP II, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    581,577 shares. (1)
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    581,577 shares. (1)
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    581,577 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.6% (2)
    12 TYPE OF REPORTING PERSON* CO

     

    (1)All such shares are held of record by Fund II. DGP II, the general partner of Fund II, and UGP II, the general partner of DGP II, may be deemed to have sole voting and dispositive power with respect to these securities. Wickham and Nakamura, the directors of UGP II, may be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 5 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sozo Ventures II-S, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    710,817 shares. (1)
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    710,817 shares. (1)
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    710,817 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.9% (2)
    12 TYPE OF REPORTING PERSON* PN

     

    (1)All such shares are held of record by Sozo Ventures II-S, L.P. (“Fund II-S”). Sozo Ventures GP II-S, L.P. (“DGP II-S”), the general partner of Fund II-S, and Sozo Ventures UGP II-S, Ltd. (“UGP II-S”), the general partner of DGP II-S, may be deemed to have sole voting and dispositive power with respect to these securities. Wickham and Nakamura, the directors of UGP II-S, may be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 6 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sozo Ventures GP II-S, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    710,817 shares. (1)
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    710,817 shares. (1)
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    710,817 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.9% (2)
    12 TYPE OF REPORTING PERSON* PN

     

    (1)All such shares are held of record by Fund II-S. DGP II-S, the general partner of Fund II-S, and UGP II-S, the general partner of DGP II-S, may be deemed to have sole voting and dispositive power with respect to these securities. Wickham and Nakamura, the directors of UGP II-S, may be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 7 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sozo Ventures UGP II-S, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    710,817 shares. (1)
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    710,817 shares. (1)
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    710,817 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.9% (2)
    12 TYPE OF REPORTING PERSON* CO

     

    (1)All such shares are held of record by Fund II-S. DGP II-S, the general partner of Fund II-S, and UGP II-S, the general partner of DGP II-S, may be deemed to have sole voting and dispositive power with respect to these securities. Wickham and Nakamura, the directors of UGP II-S, may be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 8 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sozo Ventures III, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    600,479 shares. (1)
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    600,479 shares. (1)
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    600,479 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.6% (2)
    12 TYPE OF REPORTING PERSON* PN

     

    (1)All such shares are held of record by Sozo Ventures III, L.P. (“Fund III”). Sozo Ventures GP III, L.L.C. (“GP III”), the general partner of Fund III, may be deemed to have sole voting and dispositive power with respect to these securities. Wickham and Nakamura, the managing members of GP III, may be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 9 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Sozo Ventures GP III, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    600,479 shares. (1)
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    600,479 shares. (1)
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    600,479 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.6% (2)
    12 TYPE OF REPORTING PERSON* OO

     

    (1)All such shares are held of record by Fund III. GP III, the general partner of Fund III, may be deemed to have sole voting and dispositive power with respect to these securities. Wickham and Nakamura, the managing members of GP III, may be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 10 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Phillip Wickham

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    1,892,873 shares. (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER.
    1,892,873 shares. (1)

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    1,892,873 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.1% (2)
    12 TYPE OF REPORTING PERSON* IN

     

    (1)Consists of (a) 581,577 shares of the Issuer’s Common Stock held by Fund II, (b) 710,817 shares of the Issuer’s Common Stock held by Fund II-S and (c) 600,479 shares of the Issuer’s Common Stock held by Fund III. DGP II, the general partner of Fund II, and UGP II, the general partner of DGP II, may be deemed to have sole voting and dispositive power with respect to the shares directly held by Fund II. DGP II-S, the general partner of Fund II-S, and UGP II-S, the general partner of DGP II-S, may be deemed to have sole voting and dispositive power with respect to the shares directly held by Fund II-S. GP III, the general partner of Fund III, may be deemed to have sole voting and dispositive power with respect to the shares directly held by Fund III. Wickham and Nakamura, the directors of UGP II and UGP II-S, and the managing members of GP III, may each be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 11 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Koichiro Nakamura

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)       ¨       (b)       x
    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Japan


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    1,892,873 shares. (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER.
    1,892,873 shares. (1)

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON

    1,892,873 (1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES*

    ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.1% (2)
    12 TYPE OF REPORTING PERSON* IN

     

    (1)Consists of (a) 581,577 shares of the Issuer’s Common Stock held by Fund II, (b) 710,817 shares of the Issuer’s Common Stock held by Fund II-S and (c) 600,479 shares of the Issuer’s Common Stock held by Fund III. DGP II, the general partner of Fund II, and UGP II, the general partner of DGP II, may be deemed to have sole voting and dispositive power with respect to the shares directly held by Fund II. DGP II-S, the general partner of Fund II-S, and UGP II-S, the general partner of DGP II-S, may be deemed to have sole voting and dispositive power with respect to the shares directly held by Fund II-S. GP III, the general partner of Fund III, may be deemed to have sole voting and dispositive power with respect to the shares directly held by Fund III. Wickham and Nakamura, the directors of UGP II and UGP II-S, and the managing members of GP III, may each be deemed to have shared voting and dispositive power with respect to these securities.
       
    (2)Based on 37,472,351 Common Shares of the Issuer outstanding as of March 15, 2024, as set forth in the Form 10-K.

     

     

    CUSIP NO. 59102M104 13G Page 12 of 16

     

    ITEM 1(A).NAME OF ISSUER


    Metagenomi, Inc.

     

    ITEM 1(B).ADDRESS OF THE ISSUER’S PRINCIPAL EXECUTIVE OFFICES


    5959 Horton Street, 7th Floor

    Emeryville, California 94608

     

    ITEM 2(A).

    NAME OF PERSONS FILING

     

    This Schedule 13G is being filed by Sozo Ventures - TrueBridge Fund II, L.P. (“Fund II”), Sozo Ventures GP II, L.P. (“GP II”), Sozo Ventures UGP II, Ltd. (“UGP II”), Sozo Ventures Fund II-S, L.P. (“Fund II-S”), Sozo Ventures GP II-S, L.P. (“GP II-S”), Sozo Ventures UGP II-S, Ltd. (“UGP II-S”), Sozo Ventures III, L.P. (“Fund III”), Sozo Ventures GP III, L.L.C. (“GP III”), Phillip Wickham (“Wickham”) and Koichiro Nakamura (“Nakamura”). The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    ITEM 2(B).ADDRESS OF PRINCIPAL BUSINESS OFFICE

     

    The address for each of the Reporting Persons is:

     

    10 California Street

    Redwood City, California 94063

     

    ITEM 2(C)

    CITIZENSHIP

     

    See Row 4 of cover page for each Reporting Person.

     

    ITEM 2(D).TITLE OF CLASS OF SECURITIES

     

    Common Stock, par value $0.0001 per share.

     

    ITEM 2(E).CUSIP NUMBER

    59102M104

     

    ITEM 3.Not Applicable.

     

    ITEM 4.OWNERSHIP

     

    (a)Amount beneficially owned:
    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class:
    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:
       
    (i)Sole power to vote or to direct the vote:
    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:
    See Row 8 of cover page for each Reporting Person.

     

     

    CUSIP NO. 59102M104 13G Page 13 of 16

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable.

     

    ITEM 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Under certain circumstances set forth in the limited partnership agreements of each of Fund II, Fund II-S, Fund III, DGP II and DGP II-S, the memoranda and articles of association of each of UGP II and UGP II-S, and the limited liability company agreement of GP III, the general partners, limited partners, managing members or directors, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a general partner, limited partner, managing member or director, as the case may be.

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable.

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    Not applicable.

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable.

     

    ITEM 10.CERTIFICATION

     

    Not applicable.

     

     

    CUSIP NO. 59102M104 13G Page 14 of 16

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 10, 2024

     

    Sozo Ventures - TrueBridge Fund II, L.P.   Sozo Ventures UGP II-S, Ltd.
         
    By: Sozo Ventures GP II, L.P.,   By: /s/ Phillip Wickham
      its General Partner     Phillip Wickham, Director
             
    By: Sozo Ventures UGP II, Ltd.,   By: /s/ Koichiro Nakamura
      its General Partner     Koichiro Nakamura, Director
             
    By: /s/ Phillip Wickham   Sozo Ventures III, L.P.
      Phillip Wickham, Director      
          By: Sozo Ventures GP III, L.L.C.,
    By: /s/ Koichiro Nakamura     its General Partner
      Koichiro Nakamura, Director      
          By: /s/ Phillip Wickham
    Sozo Ventures GP II, L.P.     Phillip Wickham, Director
             
    By: Sozo Ventures UGP II, Ltd.,   By: /s/ Koichiro Nakamura
      its General Partner     Koichiro Nakamura, Director
             
    By: /s/ Phillip Wickham   Sozo Ventures GP III, L.L.C.
      Phillip Wickham, Director      
          By: /s/ Phillip Wickham
    By: /s/ Koichiro Nakamura     Phillip Wickham, Director
      Koichiro Nakamura, Director      
          By: /s/ Koichiro Nakamura
    Sozo Ventures UGP II, Ltd.     Koichiro Nakamura, Director
             
    By: /s/ Phillip Wickham   /s/ Phillip Wickham
      Phillip Wickham, Director   Phillip Wickham
             
    By: /s/ Koichiro Nakamura   /s/ Koichiro Nakamura
      Koichiro Nakamura, Director   Koichiro Nakamura
             
    Sozo Ventures II-S, L.P.      
             
    By: Sozo Ventures GP II-S, L.P.,      
      its General Partner      
             
    By: Sozo Ventures UGP II-S, Ltd.,      
      its General Partner      
             
    By: /s/ Phillip Wickham      
      Phillip Wickham, Director      
             
    By: /s/ Koichiro Nakamura      
      Koichiro Nakamura, Director      
             
    Sozo Ventures GP II-S, L.P.      
             
    By: Sozo Ventures UGP II-S, Ltd.,      
      its General Partner      
             
    By: /s/ Phillip Wickham      
      Phillip Wickham, Director      
             
    By: /s/ Koichiro Nakamura      
      Koichiro Nakamura, Director      

     

     

    CUSIP NO. 59102M104 13G Page 15 of 16

     

    EXHIBIT INDEX

     

      Found on Sequentially
    Exhibit Numbered Page
       
    Exhibit A:  Agreement of Joint Filing 16

     

     

    CUSIP NO. 59102M104 13G Page 16 of 16

     

    exhibit A

     

    Agreement of Joint Filing

     

    The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the timely filing of such statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness or accuracy of the information concerning the others of the undersigned, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate or incomplete. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

     

    Date: May 10, 2024

     

    Sozo Ventures - TrueBridge Fund II, L.P.   Sozo Ventures GP II-S, L.P.
         
    By: Sozo Ventures GP II, L.P.,   By: Sozo Ventures UGP II-S, Ltd.,
      its General Partner     its General Partner
             
    By: Sozo Ventures UGP II, Ltd.,   By: /s/ Phillip Wickham
      its General Partner     Phillip Wickham, Director
             
    By: /s/ Phillip Wickham   By: /s/ Koichiro Nakamura
      Phillip Wickham, Director     Koichiro Nakamura, Director
         
    By: /s/ Koichiro Nakamura   Sozo Ventures UGP II-S, Ltd.
      Koichiro Nakamura, Director  
          By: /s/ Phillip Wickham
    Sozo Ventures GP II, L.P.     Phillip Wickham, Director
         
    By: Sozo Ventures UGP II, Ltd.,   By: /s/ Koichiro Nakamura
      its General Partner     Koichiro Nakamura, Director
         
    By: /s/ Phillip Wickham   Sozo Ventures III, L.P.
      Phillip Wickham, Director  
          By: Sozo Ventures GP III, L.L.C.,
    By: /s/ Koichiro Nakamura     its General Partner
      Koichiro Nakamura, Director    
          By: /s/ Phillip Wickham
    Sozo Ventures UGP II, Ltd.     Phillip Wickham, Director
           
    By: /s/ Phillip Wickham   By: /s/ Koichiro Nakamura
      Phillip Wickham, Director     Koichiro Nakamura, Director
         
    By: /s/ Koichiro Nakamura   Sozo Ventures GP III, L.L.C.
      Koichiro Nakamura, Director    
          By: /s/ Phillip Wickham
    Sozo Ventures II-S, L.P.     Phillip Wickham, Director
         
    By: Sozo Ventures GP II-S, L.P.,   By: /s/ Koichiro Nakamura
      its General Partner     Koichiro Nakamura, Director
         
    By: Sozo Ventures UGP II-S, Ltd.,   /s/ Phillip Wickham
      its General Partner   Phillip Wickham
         
    By: /s/ Phillip Wickham   /s/ Koichiro Nakamura
      Phillip Wickham, Director   Koichiro Nakamura
             
    By: /s/ Koichiro Nakamura      
      Koichiro Nakamura, Director      

      

     

    Get the next $MGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGX

    DatePrice TargetRatingAnalyst
    5/7/2024$10.00Buy
    H.C. Wainwright
    5/2/2024$16.00 → $6.00Overweight → Neutral
    JP Morgan
    3/5/2024Outperform
    TD Cowen
    3/5/2024$22.00Outperform
    BMO Capital Markets
    3/5/2024$16.00Overweight
    JP Morgan
    3/5/2024$23.00Buy
    Jefferies
    3/5/2024$21.00Buy
    Chardan Capital Markets
    3/5/2024$25.00Overweight
    Wells Fargo
    More analyst ratings

    $MGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Wapnick Pamela was granted 14,000 shares, increasing direct ownership by 23% to 73,684 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:58:31 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Thomas Brian C. was granted 32,000 shares, increasing direct ownership by 1% to 2,528,276 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:58:17 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Irish Jian was granted 23,000 shares, increasing direct ownership by 8% to 321,933 units (SEC Form 4)

      4 - Metagenomi, Inc. (0001785279) (Issuer)

      4/3/25 11:57:48 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Metagenomi Inc.

      SC 13G - Metagenomi, Inc. (0001785279) (Subject)

      11/6/24 4:35:15 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Metagenomi Inc.

      SC 13G - Metagenomi, Inc. (0001785279) (Subject)

      5/10/24 6:40:45 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    SEC Filings

    See more
    • Metagenomi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Metagenomi, Inc. (0001785279) (Filer)

      5/14/25 7:15:58 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Metagenomi Inc.

      10-Q - Metagenomi, Inc. (0001785279) (Filer)

      5/13/25 4:40:52 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Metagenomi, Inc. (0001785279) (Filer)

      5/13/25 4:35:07 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metagenomi Announces New Appointment to its Board of Directors

      EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi's Board of Directors, serving on Metagenomi's Audit and Compensation committees, effective January 27, 2025. "We are excited to welcome Eric to our Board of Directors," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "His tremendous track record in the pharmaceutical industry as well as his experience in business development and capital formation will be an in

      1/15/25 8:55:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MGX
    Financials

    Live finance-specific insights

    See more
    • H.C. Wainwright initiated coverage on Metagenomi with a new price target

      H.C. Wainwright initiated coverage of Metagenomi with a rating of Buy and set a new price target of $10.00

      5/7/24 6:26:47 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi downgraded by JP Morgan with a new price target

      JP Morgan downgraded Metagenomi from Overweight to Neutral and set a new price target of $6.00 from $16.00 previously

      5/2/24 6:29:35 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Metagenomi

      TD Cowen initiated coverage of Metagenomi with a rating of Outperform

      3/5/24 7:45:11 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

      Twelve-month durability data from Metagenomi's ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced data from an ongoing preclinical

      9/3/24 4:05:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

      EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base editors and RNA-mediated integration systems (RIGS), which were previously subject to exclusive rights granted to Moderna, Inc. Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1), and rights to develop the PH1

      5/1/24 4:00:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

      - Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate the ability to specifically integrate correct copies of complete genes, potentially enabling treatment of any disease caused by a loss-of-function mutation - EMERYVILLE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the presentation of three abstracts at the American Society of Gene & Cell Ther

      5/14/25 6:00:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

      - Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well capitalized with $226.0 million in cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today reported financial results for the quarter ended March 31, 2025, and provid

      5/13/25 4:30:00 PM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Metagenomi to Present at Upcoming Scientific Meetings

      EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: an oral presentation at TIDES USA 2025, taking place May 19-22, 2025, at the Manchester Grand Hyatt San Diego, and three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, LA and virtually. TIDES USA Oral Presentation Details: Title: AI-Guided Metagenomic Discovery of Compact CRISPR Systems for

      5/2/25 7:00:00 AM ET
      $MGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care